Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Audrey Koitka-Weber"'
Autor:
Piero Ruggenenti, Bettina J. Kraus, Silvio E. Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka-Weber, Christoph Wanner
Publikováno v:
EClinicalMedicine, Vol 43, Iss , Pp 101240- (2022)
Summary: Background: Diabetic kidney disease with nephrotic-range proteinuria (NRP) is commonly associated with rapid kidney function loss, increased cardiovascular risk, and premature mortality. We explored the effect of empagliflozin in patients wi
Externí odkaz:
https://doaj.org/article/fbb8fa2282594204a573a3a18cd51d49
Autor:
Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian vonEynatten, Christoph Wanner, Audrey Koitka‐Weber
Publikováno v:
Journal of Diabetes Investigation, Vol 10, Iss 3, Pp 760-770 (2019)
Abstract Aims/Introduction In the EMPA‐REG OUTCOME® trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 d
Externí odkaz:
https://doaj.org/article/37e2f4567a3542ca93e105b53c11a227
Autor:
João Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, Sabine Lauer, Bernard Zinman, David H. Fitchett, Audrey Koitka‐Weber, Jyothis T. George, Anne Pernille Ofstad, Christoph Wanner, Faiez Zannad
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 7 (2021)
Background Cardio/kidney composite end points are clinically relevant but rarely analyzed in cardiovascular trials. This post hoc analysis of the EMPA‐REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patient
Externí odkaz:
https://doaj.org/article/84d680b85e504deea50cb92bed7c4a4b
Autor:
Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J. L. Heerspink
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 18 (2020)
Background Early reduction in albuminuria with an SGLT2 (sodium‐glucose cotransporter 2) inhibitor may be a positive indicator of long‐term cardiovascular and renal benefits. We assessed changes in albuminuria during the first 12 weeks of treatme
Externí odkaz:
https://doaj.org/article/b9b63f4483434509a980385e54779671
Autor:
Cheng Wang, Anuraag R. Kansal, Anastasia Ustyugova, Matthew Stargardter, Odette Reifsnider, Egon Pfarr, Christoph Wanner, Sarah Brand, Effie Kuti, Audrey Koitka-Weber
Publikováno v:
American Journal of Kidney Diseases. 79:796-806
Rationale & Objective Benefits of sodium-glucose co-transporter 2 inhibitors on kidney outcomes have been demonstrated in clinical trials. Among patients with type 2 diabetes and established cardiovascular (CV) disease enrolled in EMPA-REG Outcome St
Autor:
William T. Abraham, Piotr Ponikowski, Audrey Koitka-Weber, Ivana Ritter, Afshin Salsali, Barbara Peil, Christoph Wanner, Martina Brueckmann, Sibylle Hauske, Stefan D. Anker, Emperial Investigators, JoAnn Lindenfeld, Egon Pfarr
Publikováno v:
Circulation. 144:1265-1267
Autor:
Christoph Wanner, David C. Wheeler, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Jyothis T. George, Adeera Levin, Vlado Perkovic
Publikováno v:
Clin J Am Soc Nephrol
Background and objectives In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), empagliflozin, in addition to standard of care, significantly reduced risk of cardiovascular death by 38%, hosp
Autor:
Stefan Hantel, Audrey Koitka-Weber, Mark E. Cooper, Silvio E. Inzucchi, Maximilian von Eynatten, Bernard Zinman, Christoph Wanner
Publikováno v:
American Journal of Kidney Diseases. 74:713-715
Autor:
Stefan Hantel, Matthew R. Weir, Audrey Koitka-Weber, Maximilian von Eynatten, Christoph Wanner, Gert Mayer, Bernard Zinman, Silvio E. Inzucchi, David Z.I. Cherney
Publikováno v:
Kidney International. 96:489-504
In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease, empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as
Autor:
Christoph Wanner, Stefan Hantel, Maximilian von Eynatten, Tomoo Okamura, Masaomi Nangaku, Takashi Kadowaki, Audrey Koitka-Weber
Publikováno v:
Journal of Diabetes Investigation
Journal of Diabetes Investigation, Vol 10, Iss 3, Pp 760-770 (2019)
Journal of Diabetes Investigation, Vol 10, Iss 3, Pp 760-770 (2019)
Aims/Introduction In the EMPA‐REG OUTCOME® trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes a